Globus Medical, Inc.

NYSE:GMED

Medical - Devices

Healthcare
$70.53 -2.71%

-$2.10 today

Market cap
$9.34B
Beta
0.95
P/E (TTM)
17.4
EPS (TTM)
$4.33
52W Low $51.79High $101.40

Volume 1.43M

Average 1.45M

GMED Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Globus Medical, Inc.NYSE: GMED

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of $151.57M fell 25.3% year over year, behind the +50.1% change in trailing-twelve-month net income. Sequentially, it rose 21.9% from the prior quarter. Over 3 fiscal years it compounded at +41.4% a year.

Context

  • Net income amounted to 18.3% of revenue in FY2025, up 14.2 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 11 analysts of $681.59M (+26.7%) for the fiscal year ending Dec 2026, a slowdown from the +422.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$151.57M+21.9% QoQ
Last fiscal yearDec 2025
$537.87M+422.3% YoY
LTMJun 2026
$535.43M+50.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.3%+36.8%+62.1 pp
1 year+422.3%+26.7%-395.6 pp
3-year CAGR+41.4%+13.6%-27.8 pp
5-year CAGR+13.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
537.87M USD
Year-over-year change
+422.3%
4-year CAGR
+37.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GMED compares with its peers on the latest reported figures

  • GMED's LTM Jun 2026 net income of $535.43M is the 4th largest of the 10 companies compared; the peer median is $1.83M.
  • Its year-over-year change of +50.1% is the 4th highest of 10, against a peer median of +24.5%.
  • Net income amounts to 17.0% of revenue for GMED, versus a peer median of 10.1%.
GMED Competitors Peer median
Net Income for GMED and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$3.73B +27.8%+11.2%14.4%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$808.5M -2.0%+34.3%9.5%
SNNSmith & Nephew plcFY2025$625M +51.7%+41.0%10.1%
GMEDGlobus Medical, Inc.LTM Jun 2026$535.43M +50.1%+41.4%17.0%
OFIXOrthofix Medical Inc.LTM Mar 2026$178.05M +24.5%+67.1%21.6%
ATECAlphatec Holdings, Inc.LTM Mar 2026$125.36M -24.3%-1.8%15.9%
KIDSOrthoPediatrics Corp.LTM Mar 2026$39.68M -2.5%—16.3%
BVSBioventus Inc.LTM Mar 2026$33.69M +201.9%—5.8%
SIBNSI-BONE, Inc.LTM Mar 2026$16.7M -37.1%-32.4%8.1%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$1.83M +115.2%—1.5%
Peer median (excluding GMED) $1.83M+24.5%+22.8%10.1%

Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income149.19M190.17M122.87M102.98M537.87M
Depreciation & Amortization69.87M68.25M144.73M254.02M276.84M
Deferred Income Tax(17.62M)(22.22M)(57.79M)(125.9M)18.63M
Stock-Based Compensation30.59M32.81M52.74M54.19M49.78M
Change in Working Capital(17.25M)(105.26M)(116.6M)(97.55M)(82.71M)
Accounts Receivables(25.9M)(50.84M)(49.91M)(78.06M)(52.18M)
Inventory(11.97M)(61.75M)(70.33M)(29.86M)(17.6M)
Accounts Payables3.68M14.42M(14.22M)17.66M8.49M
Other Working Capital16.93M(7.09M)17.87M(7.3M)(21.42M)
Other Non-Cash Items61.5M14.72M97.54M332.9M(46.96M)
Operating Cash Flow276.27M178.47M243.5M520.64M753.45M
Capital Expenditures(56.9M)(74.05M)(78.27M)(115.43M)(164.68M)
Acquisitions (Net)(34.49M)(31.44M)(296.03M)(17.64M)13.46M
Purchases of Investments(622.36M)(419.53M)(100.64M)(113.5M)(107.53M)
Sales of Investments337.81M414.65M777.91M70.52M179.49M
Other Investing Activities0000(275.75M)
Investing Cash Flow(375.94M)(110.36M)302.97M(176.05M)(355.01M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0(144.49M)(225.56M)(85.79M)(300.45M)
Dividends Paid00000
Other Financing Activities54.15M34.53M(6.26M)58.09M(378.71M)
Financing Cash Flow54.15M(109.96M)(231.82M)(27.7M)(679.16M)
Effect of Forex Changes(810K)(747K)2.18M255K22.45M
Net Change in Cash(46.33M)(42.6M)316.83M317.15M(258.28M)
Free Cash Flow219.38M104.42M165.23M405.21M588.77M

Globus Medical, Inc.

NYSE:GMED

Intrinsic Alpha fair value

Locked

Current Price

$70.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.